Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing therapies across oncology, immunology, and diabetes and cardiovascular areas.

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Eli Lilly 's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial. The ...

Metastatic Prostate Cancer Market Research 2025-2035, Featuring Key Players Such as AstraZeneca, Merck, BMS, Daiichi Sankyo, Telix, Exelixis, Eli Lilly and Co, Zenith Epigenetics, MacroGenics ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Eli Lilly stock is up 6.6% today and 50% for the year. Driving those gains is excitement over two potential blockbusters—one for obesity and diabetes and another for Alzheimer’s.